Dr Richard Scolyer, a distinguished pathologist and melanoma expert who made significant contributions to cancer research, has died at the age of 59 following a battle with inoperable grade-four brain cancer. His passing marks the loss of a prominent figure in the field of oncology, whose pioneering work in immunotherapy has transformed treatment options for melanoma patients in Australia and beyond.
A Legacy of Hope and Innovation
Scolyer’s family released a heartfelt statement that included an open letter he wrote during his illness, expressing gratitude for the overwhelming support he received throughout his journey. “Thank you for your outpouring of love and support for me and my family,” he wrote, reflecting on the connections he formed across the globe during his time as joint Australian of the Year in 2024. His words resonated with many, encapsulating a message of resilience and encouragement.
The letter also conveyed Scolyer’s desire to inspire others to pursue their dreams with humility and compassion. “If my legacy was to continue beyond these words, I would be delighted and humbled to be remembered as a proud everyday Aussie who ‘gave it a crack,’” he stated, highlighting his commitment to making a difference in the lives of others.
The Fight Against Brain Cancer
Diagnosed with glioblastoma in May 2023, Scolyer was informed he had only six to eight months left to live. In a groundbreaking move, he opted for a series of experimental immunotherapy treatments that initially slowed the aggressive tumour’s growth. However, by early 2025, the cancer made a resurgence. In a candid post on social media, Scolyer acknowledged the progression of his illness, demonstrating his characteristic resilience: “Not the best day ever… it’s not the end of the road and I’ve got more to do!”
His openness about his condition and treatment endeared him to many, as he shared both triumphs and setbacks. Just a week prior to his announcement of cancer progression, he had expressed anxiety regarding an upcoming brain scan while preparing to participate in the Tour de Cure charity cycling event in his home state of Tasmania.
Tributes from Leaders and Colleagues
Prime Minister Anthony Albanese paid tribute to Scolyer, describing him as “one of our brightest lights and one of our biggest hearts.” Albanese confirmed that Scolyer would be honoured with a state funeral, recognising the profound impact he had both as a medical professional and as a public figure. “Every day, this remarkable man… took us into his confidence and he lifted us all in the process,” Albanese remarked, acknowledging the courage Scolyer displayed in sharing his journey with the public.
Prof John Thompson from Sydney University praised Scolyer’s approachable personality and noted the significant benefits his research has brought to countless cancer patients worldwide. His collaboration with Georgina Long at Melanoma Institute Australia led to their joint recognition as Australian of the Year in 2024, celebrating their groundbreaking work in immunotherapy.
A Champion of Cancer Research
Over his illustrious career, Scolyer received numerous accolades, including nine New South Wales Premier’s Awards for Outstanding Cancer Research and the prestigious Wildfire Highly Cited Publication award. His contributions to the field were further recognised in 2021 when he was appointed an Officer of the Order of Australia.
Scolyer’s innovative research focused on the mechanisms of melanoma and the development of immunotherapy treatments, significantly advancing the understanding of cancer biology. His dedication to the field not only paved the way for new therapies but also inspired many young researchers to follow in his footsteps.
Why it Matters
Dr Richard Scolyer’s legacy extends far beyond his scientific contributions; it embodies a spirit of hope, resilience, and the relentless pursuit of knowledge in the face of adversity. His journey highlights the critical importance of research in combating cancer, as well as the profound impact that personal narratives can have on public engagement and awareness. As we mourn his passing, we are reminded of the urgent need for continued investment in cancer research and the vital role that passionate individuals like Scolyer play in shaping the future of healthcare.
